WO 2005/092866 PCT/PL2005/000022

## Claims

1. New derivatives of 4,5,6,7-tetrabromobenzimidazole of formula 1

$$\begin{array}{c|c} & Br & R_1 \\ \hline Br & N & R_2 \\ \hline Br & H & R_2 \end{array}$$

Formula 1

- wherein R<sub>1</sub> is hydrogen or aliphatic group, R<sub>2</sub> is aliphatic group optionally substituted with hydrogen or substituent such as hydroxyl group or substituted amino group.
  - **2.** A new derivative according to Claim 1, which is 2-methylamino-4,5,6,7-tetrabromo-1H-benzimidazole.
- **3.** A new derivative according to Claim 1, which is 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole.
  - **4.** A new derivative according to Claim 1, which is 2-ethanolamino-4,5,6,7-tetrabromo-1H-benzimidazole.
  - **5.** A new derivative according to Claim 1, which is 2-isopropylamino-4,5,6,7-tetrabromo-1H-benzimidazole.
- **6.** A new derivative according to Claim 1, which is 2-(2-hydroxypropylamino)-4,5,6,7-tetrabromo 1H-benzimidazole.
  - **7**. A new derivative according to Claim 1, which is 2-(2-dimethylaminoethylamino)-4,5,6,7-tetrabromo -1H-benzimidazole.
- **8.** A method of preparation of new derivatives of 4,5,6,7-tetrabromobenzimidazole of formula 1, wherein R<sub>1</sub> is hydrogen or aliphatic group, and R<sub>2</sub> is aliphatic group optionally substituted with hydrogen or substituent such as hydroxyl group or substituted amino group, in the reaction of the compound of formula 2,

Formula 2

WO 2005/092866 PCT/PL2005/000022

wherein the substituent R<sub>3</sub> is halogen, alkylthio group or alkoxy group or other group easily being substituted, with an amine, at elevated temperature, and then the resulting product is purified by crystallization or chromatography on silica gel.

**9.** The method according to Claim 8 wherein in the compound of formula 2, the substituent R<sub>3</sub> is halogen such as Cl or Br, or alkylthio group such as CH<sub>3</sub>S, C<sub>2</sub>H<sub>5</sub>S, C<sub>3</sub>H<sub>7</sub>S, or lower alkoxy, such as CH<sub>3</sub>O, C<sub>2</sub>H<sub>5</sub>O or other group easily being substituted, such as sulfone group or alkylsulfoxide group.

5

10

20

- 10. The method according to Claim 8 wherein as the amine, a primary lower aliphatic amine is used.
- **11.** The method according to Claim 10 wherein the primary aliphatic amine includes in the aliphatic chain additionally hydroxyl groups or substituted amino groups.
- **12.** The method according to Claim 8 wherein as the amine, a secondary lower aliphatic amine is used.
- **13.** The method according to Claim 8 wherein the amine is used both as a reagent and a solvent in an aqueous or alcoholic solution.
- 15 **14.** The method according to Claim 8 wherein the reaction of the compound of formula 2 with the amine is carried out within the temperature range from 80 to 140 °C.
  - **15.** The method according to Claim 8 wherein the compounds of formula 1 can be converted by a known method into salts of mineral or organic acids.
  - **16.** A pharmaceutical composition exhibiting anti-neoplastic activity, containing effective anti-neoplastic acting amount of the compound according to Claim 1, combined with at least one inert, pharmaceutically acceptable carrier or diluent.
  - **17.** A pharmaceutical composition exhibiting anti-neoplastic activity, containing effective, anti-neoplastic acting amount of the compound according to any one of Claims 2 7, combined with at least one inert, pharmaceutically acceptable carrier or diluent.
- **18.** Use of new derivatives according to Claim 1 for manufacturing of a drug having anti-neoplastic activity.
  - **19.** Use of new derivatives according to any of the Claims 2 7 for manufacturing of a drug having anti-neoplastic activity.
- **20.** A method of inhibiting caseine kinase activity 2 in patients in need of such treatment by administration of effective amount of the compound of formula 1 according to Claim 1.
  - 21. A method of inhibiting caseine kinase activity 2 in patients in need of such treatment by administration of effective amount of the compound of formula 1 according to any of the Claims 2-7.